Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.
If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...
Personal narratives on allergy and asthma conditions which contained inaccuracies gained the most traction online.
FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.
A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...
Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life's chemistry, today announced that it has initiated two ...
Learn how eczema presents differently on skin of color and the impact on mental health. Find resources for identification, ...
Around 88% of primary care providers managing patients with uncontrolled asthma reported being unfamiliar or only somewhat ...
ORLADEYO is now the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above. A capsule ...
Dec 12 (Reuters) - The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday. The drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback